At a glance
ClinicalIndex Comparison RecordN/AActive· 190 enrolled
Drug / intervention
Left Ventricular Ejection Fractionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Feasibility Study of Limited Cardiac Monitoring During Non-anthracycline Trastuzumab-based Therapy in Patients With HER2-positive Breast Cancer
In Brief
An observational study evaluating Left Ventricular Ejection Fraction for Breast Cancer. Active but no longer recruiting, targeting 190 participants across 8 sites.
Detailed Summary
The purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
N/AActive
201920202021202220232024202520262027
Enrollment StartMar 2019
First PostedJun 2019
Primary CompletionSep 2023
TodayJul 2026
Study CompletionMar 2027
First PostedJun 12, 2019
Enrollment StartMar 22, 2019
Primary CompletionSep 18, 2023
Study CompletionMar 1, 2027
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 7.1 years ago
Interventions
Left Ventricular Ejection Fractionother
LVEF assessment at baseline, 6 months, and 12 months